CARDIOGENIC SHOCK TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Takeaways from Analyst

One of the major drivers for this growth is the rising prevalence of cardiovascular diseases worldwide. Cardiogenic shock can occur as a complication of various heart conditions like heart attack, heart failure, etc. which are becoming more common. Another factor is the improving reimbursement scenario for heart failure and heart attack treatments in various developed and developing countries. This will make advanced cardiogenic shock treatments more affordable for patients and increase demand.

However, the high costs associated with cardiogenic shock medications and devices are expected to restrain the market growth to some extent. Cardiogenic shock requires intensive care and management which involves the use of costly drugs and lifesaving equipment. This acts as a barrier, especially in price-sensitive developing regions. North America is expected to continue dominating the global cardiogenic shock treatment market during the forecast period owing to the advanced healthcare infrastructure and high healthcare expenditure in the region. Within North America, the U.S. accounts for the major share due to presence of prominent players. Asia Pacific is poised to be the fastest-growing market due to rising healthcare investments, growing medical tourism, and increasing burden of heart diseases in countries like China and India.